Hypertension:评价高血压心脏受损,可用4期法,右心受累预后最差!

2019-11-08 朱朱 中国循环杂志

日本研究人员在Hypertension杂志发表的一项研究表明,一种原本在主动脉瓣狭窄患者中建立的心脏受损分期法用于高血压患者,对长期预后也有很好的预测作用。

日本研究人员在Hypertension杂志发表的一项研究表明,一种原本在主动脉瓣狭窄患者中建立的心脏受损分期法用于高血压患者,对长期预后也有很好的预测作用。

根据超声心动图显示,高血压患者的心脏受损分期4期:0期,无心脏受损;1期,左心室受损;2期,左心房或二尖瓣受损;3期,肺血管、三尖瓣或右心室受损。

研究者发现,出现0期、1期、2期、3期心脏受损的高血压患者中主要终点(全因死亡和主要不良心脏事件)的3年累积发生率分别为15.5%、20.7%、31.8%、60.6%。

校正潜在混淆因素后,心脏受损分期每增加1期,主要终点事件发生风险增加46%。

该研究回顾性纳入1639例高血压患者,这些患者不合并中重度主动脉瓣狭窄、主动脉瓣反流、二尖瓣狭窄、既往心肌梗死或心肌病。

在这些患者中,52.3%处于心脏受损0期,分别有21.8%、22%、3.8%处于心脏受损1期、2期、3期。

原始出处:
Seko Y1, Kato T1, Shiba M1, et al.Staging Cardiac Damage in Patients With Hypertension.Hypertension. 2019 Nov 4:HYPERTENSIONAHA11913797. doi: 10.1161/HYPERTENSIONAHA.119.13797. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2039115, encodeId=28362039115f8, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Apr 29 08:15:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728189, encodeId=201d1e2818947, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 15 13:15:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444595, encodeId=f70214445952f, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 10 07:15:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501409, encodeId=e67115014099b, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Nov 10 07:15:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374933, encodeId=5dce3e493311, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Nov 08 17:13:17 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2039115, encodeId=28362039115f8, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Apr 29 08:15:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728189, encodeId=201d1e2818947, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 15 13:15:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444595, encodeId=f70214445952f, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 10 07:15:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501409, encodeId=e67115014099b, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Nov 10 07:15:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374933, encodeId=5dce3e493311, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Nov 08 17:13:17 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
    2020-02-15 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2039115, encodeId=28362039115f8, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Apr 29 08:15:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728189, encodeId=201d1e2818947, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 15 13:15:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444595, encodeId=f70214445952f, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 10 07:15:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501409, encodeId=e67115014099b, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Nov 10 07:15:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374933, encodeId=5dce3e493311, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Nov 08 17:13:17 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
    2019-11-10 huagfeg
  4. [GetPortalCommentsPageByObjectIdResponse(id=2039115, encodeId=28362039115f8, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Apr 29 08:15:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728189, encodeId=201d1e2818947, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 15 13:15:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444595, encodeId=f70214445952f, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 10 07:15:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501409, encodeId=e67115014099b, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Nov 10 07:15:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374933, encodeId=5dce3e493311, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Nov 08 17:13:17 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2039115, encodeId=28362039115f8, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Apr 29 08:15:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728189, encodeId=201d1e2818947, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 15 13:15:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444595, encodeId=f70214445952f, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 10 07:15:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501409, encodeId=e67115014099b, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Nov 10 07:15:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374933, encodeId=5dce3e493311, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Nov 08 17:13:17 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
    2019-11-08 天地飞扬

    学习了,谢谢分享

    0

相关资讯

2019年日本高血压管理指南解读

2019年8月,日本高血压学会(Japanese Society of Hypertension,JSH)修订了2014年日本高血压管理指南(JSH 2014),并发表了2019年日本高血压管理指南(JSH 2019)。JSH 2019英文版共14章247页,引用参考文献1700篇,内容详尽丰富。新指南采用了两种描述方法,即除常规教科书描述方法外,还根据Minds指南手册确定了与高血压管理相关的1

Lancet: 近500万高血压数据分析:老药使心血管事件多减少15%

指南建议初始降压治疗可使用的药物包括利尿剂、血管紧张素转化酶抑制剂(ACEI)、血管紧张素Ⅱ受体阻滞剂(ARB)、钙拮抗剂等。但这些药物通过降压,预防心脑血管并发症的效果有差别吗?

Lancet:高血压单药一线治疗手段之争

研究认为,噻嗪类或类噻嗪类利尿剂单药治疗高血压的效果优于其他一线药物

Lancet Neurol:降压药与高血压人群痴呆风险

长期的观察发现,抗高血压药物可降低高血压人群痴呆风险,但对于血压正常人群则无显著效果

Hypertension:发表中美联合研究:高蛋白减肥饮食可能更利于降压

高血压与肥胖密切相关,减轻体重有助于降低血压。但是,在不同人之间,减肥引起的血压变化存在差异,这种差异可能在一定程度上与基因有关。

山东将高血压、糖尿病门诊用药纳入医保 惠及1900万患者

山东以二级及以下定点基层医疗机构为依托,将高血压、糖尿病(以下简称“两病”)参保患者门诊发生的降血压、降血糖药品费用纳入医保基金支付范围,惠及1900万“两病”医保参保患者。山东省政府11月5日召开新闻发布会,介绍该省完善城乡居民“两病”门诊用药保障机制有关情况。“高血压、糖尿病是国际公认的威胁居民健康的慢性非传染性疾病。”山东省卫生健康委员会一级巡视员钟永诚介绍说,抽样调查结果显示,2018年,